


1
2
3 **Hemophagocytic Lymphohistiocytosis-like Toxicity (carHLH) after CD19-specific CAR T-**
4 **Cell Therapy**

5
6
7
8 *Supplementary Material*

9
10 Hines et al.

11
12
13 **Supplemental Figure 1. Comparison of Ferritin in CRS and carHLH Subgroups.** Average
14 change in ferritin prior to carHLH was significantly higher compared to prior to onset of CRS
15 (**indicates significant difference; $P=0.026$; Kruskal-Wallis test). Average change per day
16 calculated as the difference in ferritin on day of carHLH diagnosis by Shah criteria (6) or CRS
17 diagnosis, compared to last available ferritin level, averaged per 24-hours. The median (horizontal
18 bar), mean (open diamond), and outliers (open circles) are shown for patients with carHLH (n=4)
19 and for CRS alone patients (n=11).
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplemental Figure 1.



Supplemental Figure 1. Comparison of Ferritin in CRS and carHLH Subgroups. Average change in ferritin prior to carHLH was significantly higher compared to prior to onset of CRS (**indicates significant difference; $P=0.026$; Kruskal-Wallis test). Average change per day calculated as the difference in ferritin on day of carHLH diagnosis by Shah criteria (6) or CRS diagnosis, compared to last available ferritin level, averaged per 24-hours. The median (horizontal bar), mean (open diamond), and outliers (open circles) are shown for patients with carHLH ($n=4$) and for CRS alone patients ($n=11$).

190x254mm (300 x 300 DPI)